 |
|
|
|
|
|
Showing Treatment 1 to 25 of 190 Next 25 |
|
Location |
|
Last Updated |
|
|
|
Details |
|
A Pilot Study to Evaluate the Effects of Vaccinations with HLA-A2-Restricted Glioma Antigen-Peptides in Combination with Poly-ICLC for Children with Newly Diagnosed Malignant or Intrinsic Brain Stem Gliomas (BSG) or Incompletely Resected Non-Brainstem High-Grade Gliomas (HGG) or Recurrent Unresectable Low-Grade Gliomas (LGG) or Recurrent High Grade Gliomas |
|
Pittsburgh, PA USA |
|
09/23/2009 |
|
|
|
|
|
Details |
|
Vaccination With Lethally Irradiated Glioma Cells Mixed With GM-K562 Cells in Patients Undergoing Craniotomy For Recurrent Tumor |
|
Boston, MA |
|
09/06/2009 |
|
|
|
Details |
|
PHASE II, single-arm, open-label investigation of HSPPC-96 vaccine with concurrent temozolomide in patients with newly diagnosed Glioblastoma Multiforme |
|
San Francisco, CA USA |
|
07/07/2009 |
|
|
|
|
|
Details |
|
Phase II Clinical Trial of Hyperbaric Oxygenation in Conjunction with Radiotherapy and Temozolomide in Adults with Newly Diagnosed Glioblastoma |
|
Mineola, NY USA |
|
06/18/2009 |
|
|
|
Details |
|
AIDS-Related Primary Central Nervous System Lymphoma: A Phase II Pilot Study of High-Dose Intravenous Methotrexate With Rituximab, Leucovorin Rescue and Highly Active Antiretroviral Therapy
|
|
Bethesda, MD USA |
|
04/22/2009 |
|
|
|
|
|
Details |
|
Multiple Ascending Dose (MAD) Study of the IGF-1R Antagonist R1507 Administered as an Intravenous Infusion in Pediatric Patients With Advanced Solid Tumors.
|
|
Bethesda, MD USA |
|
04/22/2009 |
|
|
|
Details |
|
A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas |
|
New York, NY USA |
|
04/21/2009 |
|
|
|
|
|
Details |
|
A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas |
|
Bethesda, MD USA |
|
04/21/2009 |
|
|
|
Details |
|
A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas |
|
Cincinnati,, OH USA |
|
04/21/2009 |
|
|
|
|
|
Details |
|
A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas |
|
Columbus, OH USA |
|
04/21/2009 |
|
|
|
Details |
|
A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas |
|
Toronto, Ontario, CANADA |
|
04/21/2009 |
|
|
|
|
|
Details |
|
A Feasibility Assessment and a Phase I/II Trial of MLN518 (Tandutinib) for Treatment of Patients with Recurrent Glioblastoma |
|
Winston-Salem, NC USA |
|
04/21/2009 |
|
|
|
Details |
|
A Feasibility Assessment and a Phase I/II Trial of MLN518 (Tandutinib) for Treatment of Patients with Recurrent Glioblastoma |
|
Tampa, FL USA |
|
04/21/2009 |
|
|
|
|
|
Details |
|
A Feasibility Assessment and a Phase I/II Trial of MLN518 (Tandutinib) for Treatment of Patients with Recurrent Glioblastoma |
|
Boston, MA USA |
|
04/21/2009 |
|
|
|
Details |
|
A Feasibility Assessment and a Phase I/II Trial of MLN518 (Tandutinib) for Treatment of Patients with Recurrent Glioblastoma |
|
Baltimore, MD USA |
|
04/21/2009 |
|
|
|
|
|
Details |
|
A Feasibility Assessment and a Phase I/II Trial of MLN518 (Tandutinib) for Treatment of Patients with Recurrent Glioblastoma |
|
Detroit, MI USA |
|
04/21/2009 |
|
|
|
Details |
|
A Feasibility Assessment and a Phase I/II Trial of MLN518 (Tandutinib) for Treatment of Patients with Recurrent Glioblastoma |
|
Atlanta, GA USA |
|
04/21/2009 |
|
|
|
|
|
Details |
|
A Feasibility Assessment and a Phase I/II Trial of MLN518 (Tandutinib) for Treatment of Patients with Recurrent Glioblastoma |
|
Cleveland, OH USA |
|
04/21/2009 |
|
|
|
Details |
|
A Feasibility Assessment and a Phase I/II Trial of MLN518 (Tandutinib) for Treatment of Patients with Recurrent Glioblastoma |
|
Bethesda, MD USA |
|
04/21/2009 |
|
|
|
|
|
Details |
|
A Feasibility Assessment and a Phase I/II Trial of MLN518 (Tandutinib) for Treatment of Patients with Recurrent Glioblastoma |
|
Philadelphia, PA USA |
|
04/21/2009 |
|
|
|
Details |
|
A Feasibility Assessment and a Phase I/II Trial of MLN518 (Tandutinib) for Treatment of Patients with Recurrent Glioblastoma |
|
Birmingham, AL USA |
|
04/21/2009 |
|
|
|
|
|
Details |
|
An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-Grade Glioma |
|
Bethesda, MD USA |
|
04/15/2009 |
|
|
|
Details |
|
Phase I/II study of sorafenib with radiation and temozolomide in newly diagnosed glioblastoma or gliosarcoma |
|
Houston, TX USA |
|
04/03/2009 |
|
|
|
|
|
Details |
|
Phase II study of CDX-110 with radiation and temozolomide in patients with newly diagnosed glioblastoma multiforme |
|
Houston, TX USA |
|
04/03/2009 |
|
|
|
Details |
|
Phase III, randomised, parallel Group, multi-centre study in recurrent glioblastoma patients to compare the efficacy of cediranib monotherapy and the combination of cediranib with lomustine to the efficacy of lomustine alone |
|
Houston, TX USA |
|
04/03/2009 |
|
|
|
|
|
